News and Trends 11 Nov 2022 PACT Pharma reports data from CRISPR cancer study PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients’ immune cells to treat cancer. Results from the study, which was conducted with collaborators at nine academic centers using PACT Pharma’s platforms, demonstrated early proof-of-concept that a patient’s immune system can be reprogrammed […] November 11, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 Companies with exclusive rights to CRISPR diagnostic methods sign agreement Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S. and Greater China have signed a licensing agreement. Sherlock Biosciences announced today (November 3) that it has signed a deal with China-based Tolo Biotech which grants co-exclusive rights to the Cas12 and Cas13 method patents. As the only two companies […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 The role of long-read sequencing in validating CRISPR outcomes Neil Ward, general manager of PacBio EMEA With applications of CRISPR across the spectrum of microbial, plant and gene therapy increasingly being realised, enthusiasm from the research community for this technology is not expected to wane. It has the potential to, among other applications, create knock-out animal models for use in research, revolutionise agriculture and […] October 20, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 17 Oct 2022 CRISPR gene editing: a key tool for counteracting climate change Monika Paulė, CEO and co-founder of the Lithuanian CRISPR developer Caszyme, explains how gene editing technology could fight climate change by boosting agriculture and biodiversity. The invention of CRISPR-Cas gene editing technology in the last decade sparked a revolution in biology, providing researchers a way to make selective and precise changes to an organism’s genetic […] October 17, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Way to transform Cas-9 protein into spherical nuclear acid developed A team of researchers at U.S. Northwestern University has developed a way to transform the Cas-9 protein into a spherical nuclear acid (SNA). It can then be loaded with critical components as required to access a broad range of tissue and cell types, as well as the intracellular compartments required for gene editing. The team […] October 17, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth Metastatic prostate cancer is a leading cause of cancer death in men worldwide. Interleukin (IL)-30, a cytokine that may perform immunomodulatory functions, promotes prostate cancer onset and development, but whether it can be a suitable therapeutic target remains to be investigated. In a new study published in the Journal of Hematology & Oncology, researchers at […] October 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 PerkinElmer’s Horizon Discovery: the lowdown on base editing PerkinElmer’s Horizon Discovery provides cell engineering tools and services for researchers in drug discovery and development. Horizon’s portfolio is focused on research reagents; screening and cell line engineering services; bioproduction cell lines; reference standards and base editing. Horizon’s base editing platform, Pin-point is a gene editing method with the ability to effect multiple single base edits […] October 17, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 The challenges of translating CRISPR to the clinic CRISPR-Cas9 is revolutionizing all facets of drug discovery, allowing for both a deeper understanding of disease processes, and for the development of ground-breaking genetic medicines. As these new classes of cell and gene therapies translate to the clinical setting, some key bottlenecks remain to be solved before the technology will realize its full societal impact. […] October 17, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 CRISPR/Cas9: Challenges and outlook from an investor’s perspective A Q&A with Fady Riad, CEO of consulting company Centurion Life Sciences. How did CRISPR/Cas9 revolutionize gene editing and the broader life sciences industry? CRISPR/Cas9 is undoubtedly one of the greatest scientific advancements of the last 100 years. In 2012, Jennifer Doudna and Emanuelle Charpentier published a peer-reviewed paper discussing the use of CRISPR/Cas9 in […] October 17, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 14 Oct 2022 ChristianaCare spins out new gene-editing company CorriXR Therapeutics ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute positions it […] October 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 Growing hub Lithuania ready to welcome biotech sector to EFIB’22 On October 26 and 27 the Lithuanian capital, Vilnius, is hosting the European Forum for Industrial Biotechnology & the Bioeconomy 2022 (EFIB’22). EFIB, one of Europe’s top biotech events, will bring together business leaders, entrepreneurs, scientists, and investors. Executive director of the Lithuanian Biotechnology Association, Agnė Vaitkevičienė, explains the importance of EFIB and the potential […] October 6, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Removing binding sites for an oncogene can slow cancer cell growth, researchers say Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email